Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats

Clinical and Experimental Hypertension

Volumn 25, Issue 4, 2003, Pages 221-233

  Umrani, Dhananjay N ^a   Goyal, Ramesh K ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

Fenoldopam; Insulin sensitivity; Non insulin dependent diabetes mellitus; Renal function

Indexed keywords

CHOLESTEROL; CREATININE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; GLUCOSE; INSULIN; SODIUM; STREPTOZOCIN; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY FUNCTION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; SODIUM RETENTION; TREATMENT OUTCOME; UREA BLOOD LEVEL; URINE VOLUME;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOPAMINE AGONISTS; FENOLDOPAM; HYPERTENSION, RENAL; INSULIN; INSULIN RESISTANCE; KIDNEY; LIPIDS; RATS; URINE;

EID: 0037676013     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-120020392     Document Type: Article

References (30)

1. Levin BE. Glucose-regulated dopamine release from substantia nigra neurons. Brain Res 2000; 874(2):158-164.
2. Saller CF. Dopaminergic activity is reduced in diabetic rats. Neurosci Lett 1984; 49(3):301-306.
3. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 1996; 736(1-2):54-60.
4. Lim DK, Lee KM, Ho IK. Changes in the central dopaminergic systems in the streptozotocin-induced diabetic rats. Arch Pharm Res 1994; 17(6):398-404.
5. Segers O, Dupont AG, Gerlo E, Somers G. Decreased urinary dopamine excretion and disturbed dopamine/sodium relationship in type 1 diabetes mellitus. Diabetes Med 1995; 12(3):229-234.
6. Segers O, Dupont AG, Gerlo E, Somers G. Urinary sodium and dopamine excretion: role of hyperinsulinemia in dopamine production. Med Sci Res 1996; 24:72-73.
7. Hussain T, Beheray SA, Lokhandwala MF. Defective dopamine receptor function in proximal tubules of obese Zucker rats. Hypertension 1999; 34:1091-1096.
8. Umrani DN, Hussain T, Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function and lowers blood pressure in obese Zucker rats. Am J Hypertension 2002; 15:188A.
9. Liang Y, Lubkin M, Sheng H, Scislowski PW, Cincotta H. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta 1998; 1405(1-3):1-13.
10. Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF 38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61(10):951-956.
11. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Invest Drugs 1999; 8(10):1683-1707.
12. Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta AH. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes 1999; 23:425-431.
13. Liang Y, Jetton TL, Lubkin M, Meier AH, Cincotta AH. Bromocriptine/SKF 38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998; 54(7):703-711.
14. Umrani DN, Goyal RK. Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats. Clin Exp Hypertension 2002; 24(3):207-219.
15. Bonnevie-Nielsen V, Steffes MW, Lernmark A. A major loss in islet mass and beta cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 1981; 30:424.
16. Alford FP, Martin FIR, Pearson MJ. The significance and interpretation of mildly abnormal oral glucose tolerance. Diabetologia 1971; 7:173-180.
17. Blondel O, Bailbe D, Portha B. Relation of insulin deficiency to impaired insulin action in NIDDM adult rats given streptozotocin as neonates. Diabetes 1989; 38:610-617.
18. Weir GC, Clore ET, Zmachinsky CJ, Bonner-Weir S. Islet secretion in a new experimental model for non-insulin dependent diabetes. Diabetes 1981; 30:590-595.
19. Wang RN, Bouwens L, Kloppel G. Beta cell growth in adolescent and adult rats treated with streptozotocin during the neonatal period. Diabetologia 1996; 39:548-557.
20. Bonner-Weir S, Trent DF, Honey RN, Weir GC. Responses of neonatal islets to streptozotocin: limited beta cell regeneration and hyperglycemia. Diabetes 1981; 30:64-69.
21. Iwase M, Nunoi K, Himeno H, Yoshinari M, Kikuchi M, Maki Y, Fugishima M. Susceptibility to neonatal streptozotocin-induced diabetes in spontaneously hypertensive rats. Pancreas 1994; 9:344-348.
22. Schaffer SW, Wilson GL. Insulin resistance and mechanical dysfunction in hearts of wistar rats with streptozotocin-induced non-insulin dependent diabetes mellitus. Diabetologia 1993; 36:195-199.
23. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS. The role of dopamine(D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res 1993; 27(4):335-347.
24. Barthelmebs M, Vailly B, Grima M, Velly J, Stephan D, Froehly S, Imbs JL. Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocininduced diabetes in rats. J Cardiovasc Pharmacol 1991; 18(2):243-253.
25. +-exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol 1990; 259:F297-F303.
26. 1-like dopamine receptor activation. Naunyn Schmiedebergs Arch Pharmacol 1993; 347:289-295.
27. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricentus auratus). Metabolism 1995; 44:1349-1355.
28. Mann WA, Sosnowski GF, Kavanagh BJ, Erickson RW, Brennan FJ, Wjebelhaus VD. Comparative properties of two benzazepine renal vasodilator compounds: SKF 38393-C and SKF 82526-J. Fed Proc 1981; 40:647.
29. Ackerman DM, Weinstock J, Weibelhaus VD, Berkowitz B. Renal vasodilators and hypertension. Drug Dev Res 1982; 2:283-297.
30. Feldt-Rasmussen B, Mathiesen ER, Deckert T, Geise J, Christersen NJ, Bent-Hansen L, Nielsen MD. Central role of sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone, and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Dibetologia 1987; 30:610-617.